Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
Data presented from the pivotal Phase 3 trial include an update on overall efficacy of the vaccine candidate, as well as formal analyses of secondary efficacy endpoints by serotype, baseline serostatus and disease severity −

− 18-month results build upon the efficacy and safety data reported in the 12-month analysis; overall vaccine efficacy remained generally consistent and the trial met all secondary endpoints for which there were a sufficient number of cases; safety and efficacy will be assessed over a total of four and a half years –

− Takeda presented 11 abstracts across its vaccine pipeline at ASTMH, including oral presentations on its dengue and Zika vaccine candidates −

News Agencies Feed